CN1176939C - Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine - Google Patents
Fructus gleditsiae total saponin, its preparation method and use in preparation of medicineInfo
- Publication number
- CN1176939C CN1176939C CNB021600953A CN02160095A CN1176939C CN 1176939 C CN1176939 C CN 1176939C CN B021600953 A CNB021600953 A CN B021600953A CN 02160095 A CN02160095 A CN 02160095A CN 1176939 C CN1176939 C CN 1176939C
- Authority
- CN
- China
- Prior art keywords
- fructus gleditsiae
- gleditsiae abnormalis
- total saponins
- medicine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to total saponin of Chinese honeylocust abnormal fruit for treating immune inflammation. The present invention is mainly composed oleanane type triterpenoid saponin. The present invention can be singly used or mixed with acceptable carriers in pharmacy for preparing medicine for treating immune inflammation. The present invention is particularly suitable for preparing medicine for treating rhinitis and rheumatoid arthritis. Compared with terfenadine and diclofenac sodium, the total saponin of Chinese honeylocust abnormal fruit has significant therapeutic effect.
Description
Technical field
The present invention relates to Chinese medicine Fructus Gleditsiae Abnormalis total saponins and preparation method thereof, and the application of this total saponins in preparation treatment immune inflammation disease drug, be specially extraction separation Fructus Gleditsiae Abnormalis total saponins, be used to prepare the medicine of treatment rhinitis and rheumatoid arthritis.
Background technology
Rhinitis and rheumatoid arthritis are common clinical and frequently-occurring disease, and the generation of rhinitis is main relevant with anaphylaxis, and rheumatoid arthritis belongs to autoimmune disorder, and both all belong to the category of immune inflammation.At present, the treatment rhinitis mainly adopts antihistamine drug or Claritins such as tranilast, ketotifen such as Triludan, and these medicines are relatively poor or invalid to the chronicity of rhinitis and the curative effect of showing effect repeatedly.For rheumatoid arthritis, main at present employing NSAID (non-steroidal anti-inflammatory drug) (diclofenac, acetylsalicylic acid etc.) and immunosuppressor (Ismipur etc.) are treated, but all there is tangible untoward reaction in these medicines, damage the gastrointestinal tract mucous peptide ulceration that causes as the former, the latter acts on poor selectivity, is easy to bring out infection etc.Therefore, effective constituent clear and definite, quality controllable and safely and efficiently effective ingredient in Chinese aspect development rhinitis or treating rheumatoid arthritis medicine, have potential and be worth.
The fruit that Fructus Gleditsiae Abnormalis has declined by leguminous plants Chinese honey locust Gleditsia sinensis Lam. or injured back is tied.At tcm clinical practice, be mainly used in the treatment to keep silent in the air port, larynx numbness, asthma due to excessive phlegm, ruffian is completely stagnant, carbuncle is swollen, scabies leprosy and a sore etc. (the Chinese medicine voluminous dictionary, the People's Health Publisher, Shanghai, 1977,1144-1147).Fructus Gleditsiae Abnormalis is rich in saponin component, now from its n-butanol portion separate, identified ten surplus kind of oleanane-type triterpene saponin [Phytochemistry 1999,52 (4): 715-722; J.Nat.Prod.1999,62:877-881; J.Nat.Prod.1999,62:740-745; Chem.Pharm.Bull.1999,47:388-393].Still find no the bibliographical information that closes Fructus Gleditsiae Abnormalis saponin component biological activity or clinical study up to now.
Summary of the invention
The technical problem to be solved in the present invention is how to utilize modern extraction and separation technology to obtain the efficient part total saponins of Chinese medicine Fructus Gleditsiae Abnormalis, and studies its application in preparation anti-immune inflammation medicine, as in the purposes aspect treatment rhinitis, the rheumatoid arthritis.
The technical problem to be solved in the present invention comprises that also research Fructus Gleditsiae Abnormalis total saponins can be for the preparation method of suitability for industrialized production, and the composition of Fructus Gleditsiae Abnormalis total saponins, because explicit helping of main chemical compositions carried out quality control in the suitability for industrialized production in Chinese medical extract, fundamentally guarantee the stability of the curative effect and the quality of the pharmaceutical preparations.
For solving the problems of the technologies described above, now provide technical scheme as follows.
A kind of Fructus Gleditsiae Abnormalis total saponins of anti-immune inflammation is characterized in that: by weight percentage, contain total triterpenoid saponin 50-95%, this total triterpenoid saponin is mainly the oleanane-type triterpene saponin compound.
Described Fructus Gleditsiae Abnormalis total saponins is characterized in that: can be separately or with other Chinese medicine and Chinese medical extract assembly, be used to prepare the medicine of anti-immune inflammation.
Described Fructus Gleditsiae Abnormalis total saponins is characterized in that: can mix with pharmaceutically acceptable carrier, be used to prepare the medicine of anti-immune inflammation.
Aforesaid Fructus Gleditsiae Abnormalis total saponins is characterized in that anti-immune inflammation medicine is treatment rhinitis and treatment rheumatoid arthritis medicine.
A kind of preparation method of anti-immune inflammation Fructus Gleditsiae Abnormalis total saponins is characterized in that: get Fructus Gleditsiae Abnormalis, with extraction using alcohol, the extracting solution reclaim under reduced pressure to there not being the alcohol flavor, is got ethanol extraction;
In this ethanol extraction, add ethanol and be 5-15% to containing the alcohol amount, get supernatant liquor after centrifugal, be splined on D101 type macroporous adsorptive resins, respectively with water and different concentration ethanol gradient elution, collect 60% ethanol elution thing again, get the Fructus Gleditsiae Abnormalis total saponins behind the recovery solvent;
Perhaps, get above-mentioned ethanol extraction, use chloroform extraction earlier,, collect butanol extraction liquid, get the Fructus Gleditsiae Abnormalis total saponins behind the recovery solvent again with n-butanol extraction.
The extraction using alcohol of being characterized as of described method: 30-95% 1-4 time, extract solvent load is the 6-7ml/g medicinal material at every turn, and extraction time is 1-3 hour, merges ethanol extract, and reclaim under reduced pressure gets ethanol extraction to there not being the ethanol flavor;
Get ethanol extraction, add an amount of ethanol, adjust alcohol concn to 12%, through centrifugal, supernatant liquor is splined on D101 type macroporous adsorptive resins, respectively with water, 15% ethanol, 30% ethanol and 60% ethanol elution, merges 60% ethanol elution thing, reclaim under reduced pressure, the dry extract shape thing that obtains is the Fructus Gleditsiae Abnormalis total saponins;
Perhaps, get ethanol extraction, use chloroform extraction 1-3 time, use quantity of solvent to be the 500ml/1kg medicinal material at every turn, and then, merge butanol extraction liquid with the n-butanol extraction of 500ml/1kg medicinal material 1-5 time, decompression and solvent recovery, the dry extract shape thing that obtains is the Fructus Gleditsiae Abnormalis total saponins.
Being characterized as of preceding method: use 60% ethanol, the extraction using alcohol number of times is 3 times, and extraction time is each 2 hours; The chloroform extraction number of times is 3 times, and the n-butanol extraction number of times is 3 times.
The more detailed preparation method of Fructus Gleditsiae Abnormalis extract of the present invention is as follows: Fructus Gleditsiae Abnormalis is milled to powder, with the extraction using alcohol of 30-95% 1-4 time, each extraction solvent load is 6-7ml/g, extraction time is 1-3 hour, merge ethanol extract, reclaim under reduced pressure is to there not being the ethanol flavor, add an amount of ethanol, adjust alcohol concn to 15%, through centrifugal, supernatant liquor is splined on D101 type macroporous adsorptive resins, fully after the absorption, more respectively with water, 15% ethanol, 30% ethanol and 60% ethanol elution merge 60% ethanol elution thing, reclaim under reduced pressure, the dry extract shape thing that obtains is the Fructus Gleditsiae Abnormalis total saponins.
Fructus Gleditsiae Abnormalis extract of the present invention can also prepare according to following method: Fructus Gleditsiae Abnormalis is milled to powder, with the extraction using alcohol of 30-95% 1-4 time, each extraction solvent load is 6-7ml/g, extraction time is 1-3 hour, merge ethanol extract, reclaim under reduced pressure is to there not being the ethanol flavor, with the concentrated solution of chloroform extraction gained 1-3 time, use quantity of solvent to be the 500ml/1kg medicinal material at every turn, and then with the n-butanol extraction of 500ml/1kg medicinal material 1-5 time, merge butanol extraction liquid, decompression and solvent recovery, the dry extract shape thing that obtains is the Fructus Gleditsiae Abnormalis total saponins.
In above-mentioned two kinds of preparation methods, the preferred concentration of extraction using alcohol is 60%, and preferred extraction time is 3 times, and preferred extraction time is 2 hours, and the preferred extraction times of chloroform is 3 times, and the preferred extraction times of propyl carbinol is 3 times.
The contriver finds that through further investigation Fructus Gleditsiae Abnormalis total saponins of the present invention mainly is made up of oleanane-type triterpene saponin, and wherein the content of total saponins is 50-95%.In this total saponins, contain following 8 kinds of triterpene saponin compounds, represent with GS-1～GS-8 respectively.
Fructus Gleditsiae Abnormalis total saponins of the present invention is at the oral LD of mouse
50Be 3.428g/kg, this extract 100, the 200mg/kg oral administration raises inhibited to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat due to antigen (Protalbinic acid) and the histamine, therefore, available this total saponins is made the medicine of activeconstituents preparation treatment rhinitis.
Fructus Gleditsiae Abnormalis total saponins 100 of the present invention, the 200mg/kg oral administration, rat paw edema and acetic acid induced mice writhing response due to the primary and the Secondary cases pedal swelling that obviously suppress the adjuvant arthritis rat, carrageenin show that this extract suppresses acute or chronic inflammation and pain.Therefore, available this total saponins is made activeconstituents preparation treatment rheumatoid arthritis and the diseases related medicine of other inflammation.
The suggestion clinical patients uses the dosage of Fructus Gleditsiae Abnormalis total saponins to be about one day three times 200mg/ time.Specifically can follow the doctor's advice.
Fructus Gleditsiae Abnormalis total saponins of the present invention can also be used from pharmaceutical compositions as activeconstituents and other Chinese medical extract/efficient part or with pharmaceutically acceptable excipient one, this pharmaceutical composition can adopt the ordinary method of technology of pharmaceutics to be prepared into various formulations, as parenteral dosage forms such as gastrointestinal administration formulations such as capsule, tablet, pill, oral liquid, granule, tincture and injection liquids.
Embodiment
The preparation of example 1, Fructus Gleditsiae Abnormalis total saponins of the present invention
Method 1: take by weighing Fructus Gleditsiae Abnormalis meal 1kg, add 60% ethanol 6.5L, reflux 2 hours, triplicate, merge ethanol extract, reclaim under reduced pressure adds an amount of ethanol to there not being the ethanol flavor, adjusts this solution alcohol concn to 12%, centrifugal, supernatant liquor be splined on D101 type macroporous adsorptive resins (D101 is 40～60 orders, 1Kg), fully after the absorption, successively with water, 15% ethanol, 30% ethanol and 60% ethanol elution, merge 60% ethanol elution thing (about altogether 2.0L), reclaim under reduced pressure obtains dry extract shape thing 120g.Behind the conventional qualitative experiment,, contain 74.3% saponin component in this dry extract shape thing through determined by ultraviolet spectrophotometry.This dry extract shape thing is Fructus Gleditsiae Abnormalis total saponins of the present invention.
Method: take by weighing Fructus Gleditsiae Abnormalis meal 1kg, add 60% ethanol 6.5L, reflux 2 hours, triplicate, merge ethanol extract, reclaim under reduced pressure obtains concentrated solution to there being the ethanol flavor, the concentrated solution of usefulness 500ml chloroform extraction gained 3 times, and then with the n-butanol extraction of 500ml 3 times, merge butanol extraction liquid, decompression and solvent recovery, the dry extract shape thing 164g that obtains.Behind the conventional qualitative experiment,, contain 60.5% saponin component in this dry extract through determined by ultraviolet spectrophotometry.
The acute toxicity of example 2, Fructus Gleditsiae Abnormalis total saponins of the present invention
50 of Kunming mouses, male and female half and half, body weight 18～22g, fasting is 10 hours before the administration, and 50 mouse are divided into 5 groups at random, every group 10, get Fructus Gleditsiae Abnormalis total saponins (down together), respectively orally give 5,4.25 by 1 preparation of method in the example 1 of the present invention, 3.613,3.071,2.61g/kg, between agent than being 1: 0.85, the administration volume is the 0.2ml/10g body weight, raise continuously after the administration and observed 7 days, toxicity symptom and the death condition of mouse respectively organized in record, and dead mouse is dissected, visual inspection internal organ pathology is pressed the Bliss method and is calculated LD
50And 95% fiducial limit.
The result, behind the oral Fructus Gleditsiae Abnormalis total saponins of the present invention of mouse, spontaneous activity minimizing, burnout, the volt that crouches, food-intake reduce, and death occurs in after the administration preceding 2 days, to dead mouse gross necropsy, do not see that obvious pathology takes place main organs such as the heart, liver, spleen, lung, kidney.Calculate the LD of Fructus Gleditsiae Abnormalis total saponins thus
50Value is 3.428g/kg.
Table 1 Fructus Gleditsiae Abnormalis total saponins of the present invention is at the oral acute toxicity of mouse
The dosage log10 dose number of animals death toll mortality ratio LD of probit
50Value reaches
(g/kg) (x) (%) (Y) 95% fiducial limit of (only) (only)
5 0.699 10 10 100 / LD
50：3.428
4.25 0.628 10 8 80 5.84 g/kg
3.613 0.558 10 6 60 5.25 95% fiducial limit
3.071 0.487 10 3 30 4.48 3.141～
2.61 0.417 10 1 10 3.72 3.741g/kg
Example 3, Fructus Gleditsiae Abnormalis total saponins of the present invention cause the influence of rat allergic rhinitis to Protalbinic acid
Male SD rat, body weight 180～220g, abdominal injection Protalbinic acid 1mg and aluminum hydroxide gel 10mg, injection is 1 time next day of thereafter, totally 7 times.From the 14th day beginning, splashed into 1mg/ml Protalbinic acid normal saline solution 10 μ ls, totally 7 time at rat both sides nasal cavity every day.Observe the number of times that rat in 30 minutes is sneezed and wipes nose after last instils at once, trial drug is in the Protalbinic acid last preceding 1 hour orally give that instils.
By table 2 as seen, and the Fructus Gleditsiae Abnormalis total saponins (100,200mg/kg) obviously suppress the sneeze of allergic rhinitis rat due to the Protalbinic acid and the nose reaction of scratching.Triludan 10mg/kg also presents significant inhibitory effect.
Table 2 Fructus Gleditsiae Abnormalis total saponins of the present invention causes the influence (x ± SD) of rat allergic rhinitis to Protalbinic acid
Group dosage number of animals sneeze number of times is wiped the nose number of times
(30 minutes) (30 minutes)
Control group-7 22.1 ± 6.4 28.9 ± 8.2
Fructus Gleditsiae Abnormalis total saponins 50 7 17.7 ± 5.2 23.5 ± 7.4
100 7 14.8±3.6
* 15.3±4.7
**
200 7 12.2±4.4
** 12.0±3.3
**
Triludan 10 7 15.1 ± 4.1
*16.5 ± 5.5
*
*P＜0.05,
*Compare with control group P＜0.01
The influence of the rat rhinitis that example 4, Fructus Gleditsiae Abnormalis total saponins of the present invention cause histamine
Male SD rat, body weight 180～220g, behind the rat orally give trial drug 1 hour, the both sides nasal cavity splashed into 1M histamine normal saline solution 10 μ l, observed the number of times that rat in 30 minutes is sneezed and wipes nose.
By table 3 as seen, and Fructus Gleditsiae Abnormalis total saponins of the present invention (100,200mg/kg) obviously reduce the sneeze number of times of rhinitis rat due to the histamine, the nose reaction is inhibition trend to scratching.Triludan 10mg/kg then presents significant inhibitory effect.
Table 3 Fructus Gleditsiae Abnormalis total saponins of the present invention causes the influence (x ± SD) of rat rhinitis to histamine
Group dosage number of animals sneeze number of times is wiped the nose number of times
(mg/kg) (30 minutes) (30 minutes)
Control group-7 35.5 ± 8.2 21.3 ± 6.4
Fructus Gleditsiae Abnormalis total saponins 50 7 30.3 ± 7.5 18.4 ± 6.8
100 7 26.3±5.4
* 16.7±6.4
200 7 24.8±5.5
** 15.2±5.6
Triludan 10 7 22.5 ± 3.7
*14.1 ± 4.6
*
*P＜0.05,
*Compare with control group P＜0.01
Example 5, Fructus Gleditsiae Abnormalis total saponins of the present invention cause the influence that rat nasal cavity vascular permeability raises to Protalbinic acid, histamine
Male SD rat, body weight 180～220g, observing the nasal cavity vascular permeability that Protalbinic acid and histamine cause with active sensitization rat and normal rat respectively raises, the sensitization method of rat is tested with allergic rhinitis, behind initial immunity the 14th day, rats by intraperitoneal injection vetanarcol 40mg/kg, anesthesia back from tracheae to the nasal cavity intubate, after fixing this intubate linked to each other with constant flow pump (0.25ml/min), with 37 ℃ of normal saline flushing nasal cavities 10 minutes, thereafter the blue normal saline solution 5ml/kg of rat tail vein injection 1%Evans collected perfusate 10 minutes after 3 minutes.At sensitization rat and normal rat, contain Protalbinic acid 1mg/ml and histamine 40 μ g/ml in the perfusate respectively, the perfusate of collecting from nasal cavity centrifugal 10 minutes through 1200 * g, the blue concentration of Evans in the 620nm place colorimetric estimation supernatant liquor is subjected to the reagent thing in antigen or preceding 1 hour oral administration of histamine perfusion.
By table 4 as seen, and Fructus Gleditsiae Abnormalis total saponins of the present invention (100,200mg/kg) obviously suppress the nasal cavity vascular permeability of allergic rhinitis rat due to the Protalbinic acid, 50mg/kg is inhibition trend, and Triludan 10mg/kg presents significant inhibitory effect.
Table 4 Fructus Gleditsiae Abnormalis total saponins of the present invention causes the influence that rat nasal cavity vascular permeability raises (x ± SD) to Protalbinic acid
The blue concentration inhibiting rate of group dosage number of animals Evans
(mg/kg) (μg/ml) (％)
Control group-7 0.66 ± 0.16
Fructus Gleditsiae Abnormalis total saponins 50 6 0.47 ± 0.18 28.8
100 7 0.39±0.18
** 40.9
200 7 0.33±0.12
** 50.0
Triludan 10 7 0.35 ± 0.18
*47.0
*Compare with control group P＜0.01
By table 5 as seen, Fructus Gleditsiae Abnormalis total saponins 200mg/kg of the present invention obviously reduces the nasal cavity vascular permeability of rat due to the histamine, and 100mg/kg is inhibition trend, and Triludan 10mg/kg presents significant inhibitory effect.
Table 5 Fructus Gleditsiae Abnormalis total saponins of the present invention causes the influence that rat nasal cavity vascular permeability raises (x ± SD) to histamine
The blue concentration inhibiting rate of group dosage number of animals Evans
(mg/kg) (μg/m1) (％)
Control group-6 2.12 ± 0.49
Fructus Gleditsiae Abnormalis total saponins 50 6 2.00 ± 0.37 5.7
100 6 1.86±0.22 12.3
200 6 1.56±0.25
** 26.4
Triludan 10 6 1.60 ± 0.34
*24.5
*Compare with control group P＜0.01
Example 6, Fructus Gleditsiae Abnormalis total saponins of the present invention are to the influence of rat assist agent arthritis
Mycobacterium butyricum (Difco) is ground the back mix, be made into 10mg/ml, make Freund's complete adjuvant behind the autoclaving with whiteruss.The above-mentioned adjuvant 50 μ l of the right back sufficient sole of the foot intradermal injection of male SD rat, simultaneously at afterbody apart from the about 3cm of root of the tail place intradermal injection 50 μ l, measure the left and right sufficient sole of the foot volume of rat respectively at before the injection and injection back different time, represent the swelling degree with the difference of injecting front and back.Injected the back the 16th day at adjuvant, the left back foot swelling of rat is obvious, by swelling degree and body weight rat is divided into groups, experimental group orally give Fructus Gleditsiae Abnormalis total saponins 50 of the present invention, 100,200mg/kg, positive controls orally give diclofenac 10mg/kg, control group gives isopyknic distilled water, every day 1 time, continuous 7 days, injected the back the 16th, 22 day at adjuvant, measure right back swelling degree of the paw of rat (primary reaction) and left back pedal swelling (secondary reactions), and pressed the left back sufficient sole of the foot lesion degree of following standard evaluation rat in the 22nd day.0: do not have red and swollen; 1: little toe joint is swollen slightly; 2: toe joint and pedal swelling; 3: the sufficient pawl swelling that ankle joint is following; 4: comprise the whole sufficient pawl swelling of ankle joint.
By table 6, table 7 as seen, Fructus Gleditsiae Abnormalis total saponins 100 of the present invention, the 200mg/kg oral administration, continuous 7 days, significantly suppress the primary and the Secondary cases swelling of rat assist agent arthritis, alleviate the Secondary cases pathology of rat paw.
Table 6 Fructus Gleditsiae Abnormalis total saponins of the present invention to the influence of adjuvant arthritis rat primary pedal swelling (x ± SD, n=8)
The right back swelling degree of the paw of group dosage (ml)
(mg/kg) d16 d22
Control group-1.21 ± 0.33 1.38 ± 0.22
Fructus Gleditsiae Abnormalis total saponins 50 1.17 ± 0.28 1.14 ± 0.29
100 1.36±0.3 10.73±0.30
**
200 1.40±0.27 0.61±0.24
**
Diclofenac 10 1.26 ± 0.33 0.55 ± 0.25
*
*Compare with control group P＜0.01
Table 7, Fructus Gleditsiae Abnormalis total saponins to the influence of adjuvant arthritis rat Secondary cases pedal swelling (x ± SD, n=8)
The left back swelling degree of the paw of group dosage (ml)
Integration
(mg/kg) d16 d22
Control group-0.38 ± 0.12 0.54 ± 0.16 3.5 ± 0.8
Fructus Gleditsiae Abnormalis total saponins 50 0.37 ± 0.10 0.47 ± 0.14 3.0 ± 0.6
100 0.41±0.14 0.31±0.21
** 2.4±0.9
*
200 0.40±0.13 0.28±0.12
** 1.9±1.1
**
Diclofenac 10 0.37 ± 0.13 0.25 ± 0.10
*1.7 ± 0.8
*
*P＜0.05,
*Compare with control group P＜0.01
Example 7, Fructus Gleditsiae Abnormalis total saponins on Carrageenan of the present invention cause the influence of rat paw edema
Male SD rat, experimental group orally give Fructus Gleditsiae Abnormalis total saponins 50 of the present invention, 100,200mg/kg, positive controls orally give diclofenac 10mg/kg, control group gives isopyknic distilled water, after 1 hour, 1% carrageenin physiological saline suspension 0.1ml of the right back sufficient plantar subcutaneous injection sterilization of each mouse measured the right sufficient sole of the foot volume of rat in 1,3 hour respectively at before the injection and injection back, represented the swelling degree with the difference before and after the injection.
By table 8 as seen, Fructus Gleditsiae Abnormalis total saponins 100 of the present invention, the 200mg/kg oral administration obviously alleviates rat paw edema due to the carrageenin.
Table 8 Fructus Gleditsiae Abnormalis total saponins of the present invention on Carrageenan cause rat paw edema influence (x ± SD, n=8)
The right back swelling degree of the paw of group dosage (m1)
(mg/kg) 1h 3h
Control group-0.34 ± 0.13 0.71 ± 0.21
Fructus Gleditsiae Abnormalis total saponins 50 0.29 ± 0.08 0.52 ± 0.17
100 0.20±0.14
* 0.38±0.17
**
200 0.18±0.06
** 0.29±0.15
**
Diclofenac 10 0.21 ± 0.07
*0.33 ± 0.14
*
*P＜0.05,
*Compare with control group P＜0.01
Example 8, Fructus Gleditsiae Abnormalis total saponins Dichlorodiphenyl Acetate of the present invention cause the influence of mouse writhing reaction
50 of mouse, be divided into 5 groups at random, experimental group orally give Fructus Gleditsiae Abnormalis total saponins 50 of the present invention, 100,200mg/kg, positive controls orally give diclofenac 20mg/kg, control group gives isopyknic distilled water, after 1 hour, abdominal injection 0.7% acetic acid normal saline solution 10ml/kg observes the mouse writhing reaction times in 30 minutes.
By table 9 as seen, Fructus Gleditsiae Abnormalis total saponins 100 of the present invention, the 200mg/kg oral administration significantly suppresses acetic acid induced mice writhing response.
Table 9 Fructus Gleditsiae Abnormalis total saponins of the present invention Dichlorodiphenyl Acetate cause mouse writhing reaction influence (x ± SD, n=10)
Group dosage is turned round the body number of times
(mg/kg) (20min)
Control group-47.2 ± 10.3
Fructus Gleditsiae Abnormalis total saponins 50 38.1 ± 9.5
100 25.5±10.8
**
200 21.3±8.5
**
Diclofenac 20 29.5 ± 10.6
*
*Compare with control group P＜0.01
Claims (5)
1, the application of a kind of Fructus Gleditsiae Abnormalis total saponins in the oral pharmaceutical of preparation anti-immune inflammation.
2, the described application of claim 1 is characterized in that: by weight percentage, contain total triterpenoid saponin 50-95% in the Fructus Gleditsiae Abnormalis total saponins, this total triterpenoid saponin is mainly the oleanane-type triterpene saponin compound.
3, application according to claim 1 is characterized in that: can mix with pharmaceutically acceptable carrier, be used to prepare the medicine of anti-immune inflammation.
4, application according to claim 1 is characterized in that: can be separately or with other Chinese medicine and Chinese medical extract assembly, be used to prepare the medicine of anti-immune inflammation.
5, application according to claim 1, the medicine of anti-immune inflammation comprise treatment rhinitis and treatment rheumatoid arthritis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021600953A CN1176939C (en) | 2002-12-31 | 2002-12-31 | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021600953A CN1176939C (en) | 2002-12-31 | 2002-12-31 | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429834A CN1429834A (en) | 2003-07-16 |
| CN1176939C true CN1176939C (en) | 2004-11-24 |
Family
ID=4753398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021600953A Expired - Fee Related CN1176939C (en) | 2002-12-31 | 2002-12-31 | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1176939C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083388B (en) * | 2012-12-31 | 2015-07-01 | 山东省中医药研究院 | Preparation method of fructus gleditsiae total saponins |
| CN111233963B (en) * | 2020-03-02 | 2020-11-13 | 河南中医药大学 | Active monomer for treating esophageal cancer, and composition and application thereof |
-
2002
- 2002-12-31 CN CNB021600953A patent/CN1176939C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1429834A (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1652807A (en) | Formulations useful in the treatment of male and female impotence | |
| CN1698858A (en) | Pharmaceutical composition for treating acute gout and its extraction method | |
| CN1742949A (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1923193A (en) | Application of cumarin kind compound in preparation of antiphlogistic and analgetic medicine | |
| CN1176939C (en) | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine | |
| CN1733286A (en) | A kind of compound Chinese medicinal preparation of preventing and treating alcoholic intestinal tract damage and hepatic injury | |
| CN1300175C (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN1180780C (en) | Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1672728A (en) | Extract of star of bethlehem and its prepn process, medicinal composition and use | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1436555A (en) | Medicine composition for treating acute pharyngitis and its prepn | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1313085C (en) | Application of total hypone of radix cynanchi bungei and hypnone for preparing medicine for treating gastrointestinal tract diseases | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1927290A (en) | Ointment for treating naevus and preparing method thereof | |
| CN1747740A (en) | Analgesic composition | |
| CN1267130C (en) | Chinese five-kind compound medicine for treating premenstrual symptomgroup and its preparation method | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN1241559C (en) | Chinese traditional medicine hypoglycemic agent and preparing process thereof | |
| CN1634407A (en) | Chinese traditional medicine preparation for treating cholecystitis | |
| CN1224397C (en) | Medicine for treating chronic nephritis and production process thereof | |
| CN1709329A (en) | Composition for treating female algomenorrhea and its preparing method | |
| CN1768775A (en) | Prescription containing sweet clover component and its formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041124 Termination date: 20111231 |